Chemoresistance in Pancreatic Cancer.
TLDR
New perspectives for enhancing the efficacy of gemcitabine are outlined after reviewing the related factors of gem citabine metabolism, mechanism of action, and chemoresistance.Abstract:
Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC), ranks the fourth leading cause of cancer-related deaths in the western world. While the incidence of pancreatic cancer is displaying a rising tendency every year, the mortality rate has not decreased significantly because of late diagnosis, early metastasis, and limited reaction to chemotherapy or radiotherapy. Adjuvant chemotherapy after surgical resection is typically the preferred option to treat early pancreatic cancer. Although 5-fluorouracil/leucovorin with irinotecan and oxaliplatin (FOLFIRINOX) and gemcitabine/nab-paclitaxel can profoundly improve the prognosis of advanced pancreatic cancer, the development of chemoresistance still leads to poor clinical outcomes. Chemoresistance is multifactorial as a result of the interaction among pancreatic cancer cells, cancer stem cells, and the tumor microenvironment. Nevertheless, more pancreatic cancer patients will benefit from precision treatment and targeted drugs. Therefore, we outline new perspectives for enhancing the efficacy of gemcitabine after reviewing the related factors of gemcitabine metabolism, mechanism of action, and chemoresistance.read more
Citations
More filters
Journal ArticleDOI
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Sen Yu,Chunyu Zhang,Ke-Ping Xie +2 more
TL;DR: The current therapeutic options for pancreatic cancer, and underlying mechanisms and potential reversal of therapeutic resistance, are reviewed.
Journal ArticleDOI
The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma
Rong Tang,Yiyin Zhang,Chen Liang,Jin Xu,Qingcai Meng,Jie Hua,Jiang Liu,Bo Zhang,Xianjun Yu,Si Shi +9 more
TL;DR: The findings suggest a novel anticancer strategy for restoring balanced RNA methylation in tumor cells and guide clinical physicians in developing a new practical approach for considering the impact of related genes on prognosis.
Journal ArticleDOI
The Mechanism of Warburg Effect-Induced Chemoresistance in Cancer.
Chang Liu,Ying Jin,Zhimin Fan +2 more
TL;DR: In this article, a review describes the mechanism of glycolysis-induced chemoresistance from the aspects of GAs process, signaling pathways, tumor microenvironment, and their interactions.
Journal ArticleDOI
Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study
TL;DR: Age at diagnosis is a significant and negative prognostic factor for PC, and patients diagnosed at a relatively earlier stage had the best survival; however, patients aged >80 years had a mortality risk three times that of patients aged <40 years.
Journal ArticleDOI
M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer.
TL;DR: In this article, a specific M1 macrophage-derived exosome (M1Exo)-based drug delivery system against GEM resistance in pancreatic cancer was developed, in which Deferasirox (DFX) was also loaded into drug carrier, M 1Exo, in order to inhibit ribonucleotide reductase regulatory subunit (RRM2) expression via depleting iron, and thus increase chemosensitivity of GEM.
References
More filters
Journal ArticleDOI
Cancer statistics, 2018
TL;DR: The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak.
Journal ArticleDOI
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy,Françoise Desseigne,Marc Ychou,Olivier Bouché,Rosine Guimbaud,Yves Becouarn,Antoine Adenis,Jean-Luc Raoul,Sophie Gourgou-Bourgade,Jaafar Bennouna,Jean-Baptiste Bachet,Faiza Khemissa-Akouz,Denis Péré-Vergé,Catherine Delbaldo,Eric Assenat,Bruno Chauffert,C. Montoto-Grillot,Michel Ducreux +17 more
TL;DR: FOLFIRINOX was associated with a survival advantage and had increased toxicity as compared with gemcitabine, and is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.
Journal ArticleDOI
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
H. A. Burris,Malcolm J. Moore,J. S. Andersen,M R Green,Mace L. Rothenberg,M R Modiano,M. C. Cripps,Russell K. Portenoy,A M Storniolo,P Tarassoff,R Nelson,F A Dorr,C. D. Stephens,D. D. Von Hoff +13 more
TL;DR: It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.
Journal ArticleDOI
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib,Benjamin Smith,Rhonda Aizenberg,Allison B. Rosenzweig,Julie M. Fleshman,Lynn M. Matrisian +5 more
TL;DR: Pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030, respectively.
Related Papers (5)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy,Françoise Desseigne,Marc Ychou,Olivier Bouché,Rosine Guimbaud,Yves Becouarn,Antoine Adenis,Jean-Luc Raoul,Sophie Gourgou-Bourgade,Jaafar Bennouna,Jean-Baptiste Bachet,Faiza Khemissa-Akouz,Denis Péré-Vergé,Catherine Delbaldo,Eric Assenat,Bruno Chauffert,C. Montoto-Grillot,Michel Ducreux +17 more
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff,Thomas J. Ervin,Francis P. Arena,E. Gabriela Chiorean,Jeffrey R. Infante,Malcolm J. Moore,Thomas E. Seay,Sergei Tjulandin,Wen Wee Ma,Mansoor N. Saleh,Marion Harris,Michele Reni,Scot Dowden,Daniel A. Laheru,Nathan Bahary,Ramesh K. Ramanathan,Josep Tabernero,Manuel Hidalgo,David Goldstein,Eric Van Cutsem,Xinyu Wei,Jose Iglesias,Markus F. Renschler +22 more